William Pardridge
0000-0002-2664-1338
ArmaGen, Inc.
1 paper found
Refreshing results…
Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial
Missing publications? Search for publications with a matching author name.